Met receptor juxtamembrane exon 14 alternative spliced variant: Novel cancer genomic predictive biomarker

Cancer Discovery

Volumn 5, Issue 8, 2015, Pages 802-805

  Ma, Patrick C ^a,b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b West Virginia Clinical and Translational Science Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CABOZANTINIB; CAPMATINIB; CRIZOTINIB; ERLOTINIB; ONARTUZUMAB; SCATTER FACTOR RECEPTOR; TIVANTINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL MOTILITY; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; GENETIC REGULATION; HUMAN; LUNG ADENOCARCINOMA; METASTASIS; MUTATION; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA SPLICING; STRUCTURAL CHROMOSOME ABERRATION; TREATMENT RESPONSE; ADENOCARCINOMA; ALTERNATIVE RNA SPLICING; EXON; FEMALE; GENETICS; LUNG NEOPLASMS; MALE; NEOPLASMS;

ADENOCARCINOMA; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84939204199     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0769     Document Type: Article

References (14)

1. Paik PK, Drilon A, Fan P-D, Yu H, Rekhtman N, Ginsberg MS, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5: 842-9.
2. Frampton GM, Ali SM, Rosenzweig M, Chmielecki J, Lu X, Bauer TM, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;5: 850-9.
3. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P, et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011; 1: 573-9.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
5. Frampton GM. Comprehensive genomic profi ling (CGP) of advanced cancers to identify MET exon 14 alterations that confer sensitivity to MET inhibitors. J Clin Oncol 2015; 33 (suppl; abstr 11007).
6. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small cell lung cancer. Clin Lung Cancer 2012; 13: 391-5.
7. Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol 2012; 7: 459-67.
8. The Cancer Genome Atlas Research Network. Comprehensive molecular profi ling of lung adenocarcinoma. Nature 2014; 511: 543-50.
9. Camidge DR, Ou SHI, Shapiro G, Otterson GA, Villaruz LC, Villalona- Calero MA, et al. Effiffcacy and safety of crizotinib in patients with advanced c-MET-amplifi ed non-small cell lung cancer (NSCLC). J CLin Oncol 32:5s, 2014(suppl; abstr 8001).
10. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. C-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272-81.
11. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-88.
12. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66: 283-9.
13. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014; 5: 4846.
14. Liu X, Jia Y, Shen Y, Chen J, Mansukhani M, Cheng HI, et al. Detection of frequent MET exon skipping events in pulmonary sarcomatoid carcinoma and response to targeted inhibition. J Clin Oncol 33, 2015 (suppl; abstr 8020).